ITonis Inc (OTCMKTS:ITNS) Climbs Then Crashes

Shares of ITonis Inc (OTCMKTS:ITNS) exploded up the charts after getting picked up Epic Stock Picks and Stock of the Week group on Tuesday. Then the newsletter Penny Picks picked up the stock as well. Unfortunately, after only a one day climb, shares came right back down. What ended up happening is that besides regular subscribers following these newsletters, a number of short sellers follow them as well. When the Epic followers went to book their profits, their selling was met by the short sellers and shares collapsed.Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc, which allows the company to use MyEChecks patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries.Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.EMESYL is an over-the-counter, systemically active preparation delivered via nasal spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current prescription treatments. EMESYL Nausea Relief represents a paradigm shift in the way nausea is treated. As a nasal spray, EMESYL Nausea Relief is able to bypass GI processing in order get to the root of the problem. The result is fast relief.Last month, ITNS announced that National Homeopathic Labs will be the new manufacturer for its anti-nausea product, EMESYL. National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that has specialized in formula development and packaging of homeopathic, nutritional, cosmeceutical, and dietary supplements for over 25 years. Itonis has placed its first purchase order with National Homeopathic Labs and is expecting delivery of its first batch of product within the next 2 months.ITNS also plans to begin airing its planned Ten Thousand (10,000) thirty (30) second commercial spots for its EMESYL product upon delivery of its first batch of product from National Homeopathic Labs. A previously signed agreement to provide marketing and public relations services for its EMESYL product calls for placing the 10,000 commercial spots in select regional areas on the most popular cable television networks available. The networks available to Itonis for airing selection choice include ESPN, CNN, Fox News, Discovery Channel, SPIKE, AMC, TBS, Lifetime, A&E, Comedy Central, TV Land, Nickelodeon, Travel Channel, ESPN2, USA, HLN, BET, MTV, SyFy, CMT, TLC, TNT, and FX, etc., and have the ability to air more frequently in any of these select networks.Currently trading with a market cap of $3.8 million, ITNS is an exciting story on the OTC markets with a nasal spray product that has gotten great reviews on Amazon. Unfortunately, the stock has been attacked by the shorts and we expect this might continue until the company can ramp up sales of EMESYL. Once that happens, we expect a short covering rally to occur. We will be updating Insider Financial as soon as we know more. For continuing coverage on ITNS, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in ITNS and have not been compensated for this article.